IP Library Granted Patent US 11,406,690
Granted Patent B2
US 11,406,690 · App. 16/588,130 · Granted Aug 9, 2022

Adeno-associated virus factor VIII vectors

Inventors: Peter Cameron Colosi (Novato, CA); Amit Nathwani (London, GB); Jenny McIntosh (London, GB); Edward Tuddenham (London, GB); Andrew Davidoff (Memphis, TN)
Assignees: BIOMARIN PHARMACEUTICAL INC.; UCL BUSINESS LTD; ST. JUDE CHILDREN'S RESEARCH HOSPITAL
A61K38/37A61K48/0058A61K48/0066C07K14/755C12N7/00C12N15/86C12N2750/14132C12N2750/14142C12N2750/14143C12N2750/14151C12N2800/22C12N2830/008
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,406,690
App. No.
16/588,130
Granted
Aug 9, 2022
Kind
B2
Abstract

The present disclosure provides methods of generating multiplexed genetically modified animals, for example, porcine endogenous retrovirus (PERV)-inactivated pigs. The disclosure also provides methods of improving the birth rate of multiplexed genetically modified animals. In some embodiments, the present closure is concerned with the generation and utilization of porcine cells in which porcine endogenous retroviral (PERV) elements have been inactivated. In sonic embodiments, the PERV-free or PERV-reduced porcine cells are cloned to produce porcine embryos. In some embodiments, the PERV-free or PERV-reduced embryos may be grown into adult swine from which organs and/or tissues may be extracted and used for such purposes as xenotransplantation into non-porcine animals such as humans.

Claims (7)

1. An adeno-associated virus (AAV) Factor VIII (FVIII) vector comprising a nucleic acid comprising an inverted terminal repeat (ITR), a liver-specific transcription regulatory region, and a functionally active FVIII coding region, wherein the functionally active FVIII coding region comprises nucleotides 923-5296 of SEQ ID NO: 9.

2. A method of producing a recombinant adeno-associated virus (AAV) particle comprising

A) culturing a cell that has been transfected with a AAV vector of claim 1 ; and

B) recovering recombinant AAV particle from the supernatant of the transfected cell.

3. A viral particle comprising the viral vector of claim 1 .

4. An isolated cell comprising the viral vector of claim 1 .

5. A method of treating a patient suffering from hemophilia A comprising intravenously administering to the patient an effective amount of an AAV FVIII vector of claim 1 .

Assignments (5)
SECURITY INTEREST Recorded Apr 27, 2026
From: BIOMARIN PHARMACEUTICAL INC.; AMICUS THERAPEUTICS, INC.
To: CITIBANK, N.A., AS COLLATERAL AGENT
Reel/Frame 075493/0968 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 8, 2022
From: DAVIDOFF, ANDREW
To: ST. JUDE CHILDREN'S RESEARCH HOSPITAL
Reel/Frame 058925/0748 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 10, 2020
From: COLOSI, PETER CAMERON
To: BIOMARIN PHARMACEUTICAL INC.
Reel/Frame 053737/0690 →
NUNC PRO TUNC ASSIGNMENT Recorded Sep 10, 2020
From: NATHWANI, AMIT; MCINTOSH, JENNY; TUDDENHAM, EDWARD
To: UNIVERSITY COLLEGE LONDON
Reel/Frame 053753/0063 →
NAME CHANGE Recorded Aug 4, 2020
From: UCL BUSINESS PLC
To: UCL BUSINESS LTD
Reel/Frame 053397/0183 →
Continuity (4)
Continuation 15294310 · Oct 14, 2016
Continuation 14482648 · Sep 10, 2014
Provisional Application 61877042 · Sep 12, 2013
Related Publication 20200101140A1 · Apr 2, 2020